SCHEMBL6701818

SCHEMBL6701818

CCCCCn1cncc1C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TBXAS1 P24557 2/20 0.38
HCAR3 P49019 1/20 0.37
CDC25A P30304 1/20 0.37
TLR8 Q9NR97 4/20 0.37
CYP1A2 P05177 3/20 0.36
CYP2C19 P33261 3/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36
CYP2C9 P11712 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE4A P27815 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CNR2 P34972 4/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23930976 0.95 ALDH1A1 (0.40) TDP1ALDH1A1TBXAS1HCAR3CYP1A2
SCHEMBL1422382 0.83 ALDH1A1 (0.36) TDP1ALDH1A1HCAR3
SCHEMBL5726023 0.83 CYP11B1 (0.50) TDP1TLR8CYP1A2CYP2C19GAA
SCHEMBL8799103 0.81 CYP11B1 (0.49) TDP1TBXAS1TLR8CYP1A2CYP2C19
SCHEMBL15202361 0.81 GABRA1 (0.47) ALDH1A1CYP1A2CYP2C19CYP2C9CNR2
SCHEMBL9819383 0.80 ALDH1A1 (0.44) TDP1ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL23930932 0.78 CYP11B1 (0.51) TDP1ALDH1A1TLR8CYP1A2CYP2C19
SCHEMBL27922993 0.74 ADORA2A (0.40) TDP1ALDH1A1CYP1A2CYP2C19GAA
SCHEMBL5105361 0.74 PDE4A (0.35) CYP1A2CYP2C19CYP2C9PDE4AADORA2A
SCHEMBL31203742 0.73 KDM4C (0.37) TDP1ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101550106-A Industrialized preparation method of N-alkyl substituted-imidazole-5-carboxylic-acid/ester compound SHANGHAI APPTEC CO LTD (CN) 2009-10-07 CN disclosed
WO-2004078714-A2 PROCESSES FOR PREPARING IMIDAZOQUINOXALINONES, HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINONES, IMIDAZOUINOXALINES AND HETEROCYCLIC-SUBSTITUTED IMIDAZOPYRAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-16 WO disclosed
US-20040180898-A1 Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines BRISTOL-MYERS SQUIBB COMPANY 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180898-A1 Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines NISCH, PDXK, IPO4 TDP1 3206/4885ALDH1A1 3284/4885TBXAS1 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.